Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker
Year: 2020
Type: article
Abstract: < 0.05) based on NCI-60 cancer cell line panel. DYNC1H1 was high frequently alteration in GC and was positively associated with TMB-H and MSI-H. Mutant DYNC1H1 may be accompanied with down-regulation of MTIs-related genes in GC or change the binding pocket to sensitize MTIs. Overall, this study suggested that some MTIs may be the best candidate drugs to treat GC with high immune activity, especially patients with DYNC1H1 mutated.
Source: Aging
Authors: Jin Bai, BoWen Yang, Ruichuan Shi, Xinye Shao, Yujing Yang, Fang Wang, Jiawen Xiao, Xiujuan Qu, Yunpeng Liu, Ye Zhang, Zhi Li
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1845273686, G3120112937, G6859842260
OpenAlex ID: W3107345352